Compare FNUC & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FNUC | IMA |
|---|---|---|
| Founded | 2018 | 2019 |
| Country | Canada | United States |
| Employees | N/A | 15 |
| Industry | Other Metals and Minerals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.5M | 54.8M |
| IPO Year | 2021 | N/A |
| Metric | FNUC | IMA |
|---|---|---|
| Price | $2.11 | $5.74 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 202.5K | ★ 384.9K |
| Earning Date | 06-24-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.89 | $3.94 |
| 52 Week High | $2.82 | $17.50 |
| Indicator | FNUC | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 43.80 | 51.06 |
| Support Level | $2.00 | $5.52 |
| Resistance Level | $2.82 | $7.17 |
| Average True Range (ATR) | 0.20 | 0.40 |
| MACD | -0.06 | 0.03 |
| Stochastic Oscillator | 1.39 | 35.41 |
Frontier Nuclear and Minerals Inc is developing a U.S.-focused front-end nuclear fuel cycle company through a portfolio of U.S. uranium exploration and development projects in Wyoming, Colorado, and Utah, together with investments in next-generation uranium enrichment and small modular reactors. Frontier Nuclear is actively evaluating value-accretive investment opportunities in other sectors of the domestic U.S. nuclear fuel cycle. The group is developing a portfolio of critical minerals projects in America, Canada, and Namibia, including uranium, tantalum, cesium, and lithium. Its projects are Engo Valley, Pine Ridge, Shatford Lake, Snow Lake Lithium, and Tallahassee.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.